Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12AS6 | ISIN: IM00B6QH1J21 | Ticker-Symbol: V77
Frankfurt
05.11.24
08:04 Uhr
0,024 Euro
0,000
0,00 %
1-Jahres-Chart
AGRONOMICS LIMITED Chart 1 Jahr
5-Tage-Chart
AGRONOMICS LIMITED 5-Tage-Chart
ACCESSWIRE
426 Leser
Artikel bewerten:
(2)

Agronomics Limited Announces Meatable awarded €7.6 million Innovation Credit

DOUGLAS, ISLE OF MAN / ACCESSWIRE / September 24, 2024 / Agronomics, a leading listed company in the field of cellular agriculture, is pleased to announce that its portfolio company, Meatable B.V. ("Meatable"), has secured €7.6 million in funding under the Innovation Credit programme from the Netherlands Enterprise Agency.

The programme is intended for the development of innovative development projects that are proven to have a good degree of technical feasibility and excellent market prospects. The funding is in the form of milestone linked credit payments that are spread out across the period and will be repaid following the completion of the project. Meatable will use the credit to further improve productivity and reduce costs in the lead-up to commercialisation.

Meatable has rapidly emerged as a frontrunner in the field of cultured meat, having raised approximately €97 million to date including a €30 million Series B funding round in August 2023. Meatable has also recently achieved a groundbreaking milestone by hosting Europe's first public tasting of its cultivated meat products at its headquarters in Leiden, Netherlands. In addition, Meatable announced in April that it had achieved a 50% reduction in production times for its pork sausage from 8 days to just 4.

Agronomics Co-Founder and Executive Chair Jim Mellon commented:

"The new funding awarded to Meatable is a testament to its innovative approach and the immense potential of cultured meat. As global meat consumption continues to rise, traditional livestock production methods are facing increasing pressure to meet demand while mitigating environmental impacts. Meatable's innovative approach offers a promising solution by producing meat without the need for animal slaughter, thereby reducing carbon emissions, water consumption, and land use. We are excited to see Meatable enter the next stage of growth as it achieves regulatory approval and commercialises its products."

The full announcement is set out below without any material changes:

September 2024 - Meatable has been awarded EUR 7.6 million under the Innovation Credit program by the Netherlands Enterprise Agency (RVO). The RVO Innovation Credit is intended for the development of innovative development projects with considerable technological risks and excellent market prospects. Meatable will use the credit to further improve productivity and reduce costs in the lead-up to commercialisation.

Demand for meat continues to grow rapidly. Already, as many as 828 million people - or 10% of the world's population - go to bed hungry each night. To keep up with this demand, the required supply increases under current livestock production methods will have further devastating impact on the environment and society. Cultivated meat is set to be part of the solution - one single sample of cells has the potential to feed the world, without any of the environmental or societal drawbacks.

Meatable has developed a unique technology platform to produce cultivated meat and will work as a partner to the meat industry to roll out products at scale. The Innovation Credit comes on top of Meatable's 2023 $35 million Series B funding round and will bring the company one step closer to fulfilling its vision of satisfying the world's appetite for meat, without harming people, animals or the planet.

The Netherlands Enterprise Agency helps entrepreneurs and organisations to invest, develop and expand their businesses and projects, both in the Netherlands and abroad. RVO is a government agency and part of the Dutch Ministry of Economic Affairs.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Capital Markets Limited

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Charlie Combe

Lucy Williams

Charles Goodfellow

Bob Huxford

Anthony Hughes

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Agronomics Limited



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.